Chicago—While treatment of Crohn’s disease and ulcerative colitis (UC) has been greatly improved by the introduction of biologic therapies such as infliximab, which targets tumor necrosis factor alpha, the greater effectiveness has come at significant cost. A recent analysis published in Alimentary Pharmacology & Therapeutics offers evidence that a new and lower cost biosimilar for infliximab—called CT-P13 (Remsima/Inflectra) has excellent clinical efficacy and safety. University of Chicago–led researchers came to that conclusion based on 11 published studies including 829 patients. Researchers report that the induction of clinical response in Crohn’s disease and UC was achieved in more than 70% of patients at short (8-14 weeks) and medium (24-30 weeks) terms. Study authors note that CT-P13 has been recently approved in the United States, the European Union, Australia, Canada, and Japan.
« Click here to return to The MTM Review.